Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Inclusion Criteria: * \> 18 years old Documented HIV-1 infection. * Has voluntarily signed ICF. * On HAART ≥ 2 years, without changes in the 24 weeks immediately prior to screening. * HIV viral load \<50 copies/mL, and never \> 50 copies/mL on 2 consecutive occasions in the last 2 years. CD4 count nadir. * \> 350 cells/ mm3 Current CD4 count \> 500 cells/ mm3. * R5 HIV-1 at Screening as defined by proviral DNA genotropism. Exclusion Criteria: A subject will NOT be eligible for study participation if he/she meets ANY of the following criteria: * Any evidence of an active AIDS-defining condition. * Any significant acute medical illness in the past 8 weeks. * Women who are pregnant or breastfeeding. * Use of any of the following within 90 days prior to entry: systemic cytotoxic chemotherapy; investigational agents; immunomodulators (colony-stimulating factors, growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons); coumadin, warfarin, or other Coumadin derivative anticoagulants. Use of an agent definitely or possibly associated with effects on QT intervals: amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine. * Receipt of compounds with HDAC inhibitor-like activity, such as valproic acid or nicotinamide within the last 30 days. Potential participants may enroll after a 30-day washout period. * Known hypersensitivity to the components of gold salt, nicotinamide or its analogs. * Hepatitis B (HBsAg +) or Hepatitis C (HCV RNA +) infection. * Known renal insufficiency defined as calculated creatinine clearance (Cockcroft Gault formula) \<60 mL/min. * Subjects with a laboratory abnormality grade 3 or 4 with the following exceptions: pancreatic amylase, cholesterol, triglyceride, gamma glutamyl transpeptidase, bilirubin. * Any condition which, in the investigators opinion, could compromise the subject's safety or adherence to the trial protocol.